Janux Therapeutics designates Zachariah McIver as Vice President, Clinical Development
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, yesterday announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years […]
IMV Inc. changes its Board of Directors
IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, yesterday announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors (“Board”) of the Company, effective immediately. Dr. Tilley, Managing Partner at CTI […]
